RE:RE:RE:RE:RE:I don't see any defamation on this stockhouse boardCare Oncology brought in nearly $1 million per quarter and Stage acquired it for 14.9 million shares or at today's price of $1.3 million. A company worth $10-15 million for $1.3 million.
Stage is using the Covid revenue and now Care Oncology revenue to maintain operations and scale out Aristotle. You obviously have never owned a company or been an executive before.
The improvement by quarter, the pivot into Covid and acquistion of Care Oncology were excellent moves. Aristotle will get traction and if you were listening to the CC or read the MD&A you would understand how Aristotle is growing.
This should not be at these near 52 week lows but you can see the spamming and need to bury posts from the bashers. Ask why they feel the need to continually post today? If the company was done as they suggest the board would dry up and they would move on. They want to short, they want to keep the SP down for the toxic fianciers but Tripp has the means to keep revenue growing with Care Oncology and will move the funds into Aristotle scale out.
The company is taking steps to profitability and they are getting worried.
Liked2Think wrote: I again think you are making too much of things as I lost all faith in this company quite some time ago.
I hope you end up being rewarded for your continued faith but I doubt that you will.
Tripp said CARE made $1M a quarter when they were bought I am 100% sure of it.
Lets say he was rounding up like no tomorrow and they actually were making $500,001 a quarter.
That means after 16 months both companies combined made another $500K on top of that.
Makes it sound extremely pathetic.